Prime Medicine (PRME) Change in Account Payables (2021 - 2026)
Prime Medicine (PRME) reported Change in Account Payables of $3.6 million for Q1 2026, up 88.54% on a YoY basis from $1.9 million in Q1 2025, and up 711.36% quarter-over-quarter from -$581000.0 in Q4 2025.
Prime Medicine (PRME) Change in Account Payables (2021 - 2026) Analysis & Trends
Prime Medicine has reported Change in Account Payables for 6 years, with the latest figure at $3.6 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables rose 88.54% year-over-year to $3.6 million; the trailing twelve-month figure through Mar 2026 stood at $2.7 million (up 6.26% YoY), and the FY2025 full-year result was $996000.0, up 118.95% from the prior year.
- Change in Account Payables for Q1 2026 stood at $3.6 million, up from -$581000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $5.8 million in Q3 2023, with the low at -$5.9 million in Q1 2024.
- Historically, Change in Account Payables has averaged $640529.4 across 5 years, with a median of $1.4 million in 2022.
- Annual changes were most pronounced in 2023 — Change in Account Payables jumped 1535.66% — and 2024, when it slumped 1066.67%.
- Prime Medicine's Change in Account Payables stood at $431000.0 in 2022, then soared by 428.77% to $2.3 million in 2023, then advanced by 7.94% to $2.5 million in 2024, then sank by 123.62% to -$581000.0 in 2025, then soared by 711.36% to $3.6 million in 2026.
- The last three Change in Account Payables figures came in at $3.6 million (Q1 2026), -$581000.0 (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Prime Medicine | 572.02 Mn | 572.02 Mn | - | 3.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.55 Mn |
| Mar 31, 2026 | 3.55 Mn |
| Dec 31, 2025 | -581,000.00 |
| Dec 31, 2025 | -581,000.00 |
| Sep 30, 2025 | 3.04 Mn |
| Sep 30, 2025 | 3.04 Mn |
| Jun 30, 2025 | -3.35 Mn |
| Jun 30, 2025 | -3.35 Mn |
| Mar 31, 2025 | 1.88 Mn |
| Mar 31, 2025 | 1.88 Mn |
| Dec 31, 2024 | 2.46 Mn |
| Dec 31, 2024 | 2.46 Mn |
| Sep 30, 2024 | 1.51 Mn |
| Sep 30, 2024 | 1.51 Mn |
| Jun 30, 2024 | -3.35 Mn |
| Jun 30, 2024 | -3.35 Mn |
| Mar 31, 2024 | -5.88 Mn |
| Mar 31, 2024 | -5.88 Mn |
| Dec 31, 2023 | 2.28 Mn |
| Dec 31, 2023 | 2.28 Mn |